Hospital de dia Quiron Zaragoza

Zaragoza 50012

0 studies enrolling now · 7 studies all time

What they study most

Fabry Disease, Follicular Lymphoma, Myelofibrosis, Previously Treated PH + CML

Studies at this site

• Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease — Completed
• Extension Study of PRX-102 for up to 60 Months — Completed
• Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients — Completed
• Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function — Completed
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib — Status unconfirmed
• Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors — Stopped early
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed